Hyperprolactinaemia: Analysis of presentation, diagnosis and treatment in the endocrine service of a general hospital

Irish Medical Journal

Volumn 93, Issue 3, 2000, Pages 74-76

  Suliman, A M ^a   Al Saber, F ^a   Hayes, F ^a   Fiad, T ^a   Culliton, M ^a   Cunningham, S ^a   McKenna, T J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT;

AMENORRHEA; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; ENDOCRINE DISEASE; EPILEPSY; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IMPOTENCE; INFERTILITY; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; VISUAL FIELD DEFECT;

BROMOCRIPTINE; COMBINED MODALITY THERAPY; FEMALE; HORMONE ANTAGONISTS; HOSPITALS, TEACHING; HUMANS; HYPERPROLACTINEMIA; MAGNETIC RESONANCE IMAGING; MALE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0033812402     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Progress in the management of hyperprolactinaemia
2. Clinical history and outcome of 59 patients with idiopathic hyperprolactinaemia
3. Idiopathic hyperprolactinaemia: What should we do about it?
4. A homologus radio-immunoassay for human prolactin
5. Long-term follow-up of patients with hyperprolactinaemia
6. Decreased bone density in hyperprolactinemic women
7. Osteoporosis in men with hyperprolactinemic hypogonadism
8. Suppression of pituitary tumour growth and function by ergot alkaloids
9. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
10. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two doses level in hyperprolactinemic patients
11. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation, randomised, double, multicentre study
12. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicenter study
13. Cabergoline: Long-acting oral treatment of hyperprolactinemic disorders
14. Cabergoline in the long-term therapy of hyperprolactinemic disorders
15. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolacinemic patients
16. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea
17. Clinical management of prolactinoma: A ten year experience
18. Morphological studies on mixed growth hormone (GH) and prolactin (PRL)-secreting humane pituitary adenomas. Coexistence of GH and PRL in the same secretory granule
19. Human mixed somatotrophic and lactotrophic pituitary adenoma